317 related articles for article (PubMed ID: 25264898)
1. Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells.
Kakar SS; Ratajczak MZ; Powell KS; Moghadamfalahi M; Miller DM; Batra SK; Singh SK
PLoS One; 2014; 9(9):e107596. PubMed ID: 25264898
[TBL] [Abstract][Full Text] [Related]
2. DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancer.
Kakar SS; Worth CA; Wang Z; Carter K; Ratajczak M; Gunjal P
J Cancer Stem Cell Res; 2016; 4():. PubMed ID: 27668267
[TBL] [Abstract][Full Text] [Related]
3. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
5. Enrichment for chemoresistant ovarian cancer stem cells from human cell lines.
Cole JM; Joseph S; Sudhahar CG; Cowden Dahl KD
J Vis Exp; 2014 Sep; (91):51891. PubMed ID: 25285606
[TBL] [Abstract][Full Text] [Related]
6. Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells.
Kakar SS; Parte S; Carter K; Joshua IG; Worth C; Rameshwar P; Ratajczak MZ
Oncotarget; 2017 Sep; 8(43):74494-74505. PubMed ID: 29088802
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
8. Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.
Wu D; Wang J; Cai Y; Ren M; Zhang Y; Shi F; Zhao F; He X; Pan M; Yan C; Dou J
J Ovarian Res; 2015 Oct; 8():68. PubMed ID: 26497895
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Jagged1 mRNA in human epithelial ovarian carcinoma tissues and effect of RNA interference of Jagged1 on growth of xenograft in nude mice].
Liu GY; Gao ZH; Li L; Song TT; Sheng XG
Zhonghua Fu Chan Ke Za Zhi; 2016 Jun; 51(6):448-53. PubMed ID: 27356481
[TBL] [Abstract][Full Text] [Related]
13. Stem cell characteristics of dormant cells and cisplatin‑induced effects on the stemness of epithelial ovarian cancer cells.
Zhou N; Wu X; Yang B; Yang X; Zhang D; Qing G
Mol Med Rep; 2014 Nov; 10(5):2495-504. PubMed ID: 25119644
[TBL] [Abstract][Full Text] [Related]
14. Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture.
Chen J; Wang J; Zhang Y; Chen D; Yang C; Kai C; Wang X; Shi F; Dou J
J Biosci Bioeng; 2014 Aug; 118(2):214-22. PubMed ID: 24684961
[TBL] [Abstract][Full Text] [Related]
15. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
17. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
[TBL] [Abstract][Full Text] [Related]
18. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
[TBL] [Abstract][Full Text] [Related]
19. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
20. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
